Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
2 "Radiofrequency ablation"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Gastrointestinal cancer
Radiofrequency Ablation versus Stereotactic Body Radiation Therapy in the Treatment of Colorectal Cancer Liver Metastases
Jesang Yu, Dong Hwan Kim, Jungbok Lee, Yong Moon Shin, Jong Hoon Kim, Sang Min Yoon, Jinhong Jung, Jin Cheon Kim, Chang Sik Yu, Seok-Byung Lim, In Ja Park, Tae Won Kim, Yong Sang Hong, Sun Young Kim, Jeong Eun Kim, Jin-hong Park, So Yeon Kim
Cancer Res Treat. 2022;54(3):850-859.   Published online October 13, 2021
DOI: https://doi.org/10.4143/crt.2021.674
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to compare the treatment outcomes of radiofrequency ablation (RFA) and stereotactic body radiation therapy (SBRT) for colorectal cancer liver metastases (CRLM) and to determine the favorable treatment modality according to tumor characteristics.
Materials and Methods
We retrospectively analyzed the records of 222 colorectal cancer patients with 330 CRLM who underwent RFA (268 tumors in 178 patients) or SBRT (62 tumors in 44 patients) between 2007 and 2014. Kaplan–Meier method and Cox models were used by adjusting with inverse probability of treatment weighting (IPTW).
Results
The median follow-up duration was 30.5 months. The median tumor size was significantly smaller in the RFA group than in the SBRT group (1.5 cm vs 2.3 cm, p<0.001). In IPTW-adjusted analysis, difference in treatment modality was not associated with significant differences in 1-year and 3-year recurrence-free survival (35% vs 43%, 22% vs 23%; p=0.198), overall survival (96% vs 91%, 58% vs 56%; p=0.508), and freedom from local progression (FFLP; 90% vs 72%, 78% vs 60%; p=0.106). Significant interaction effect between the treatment modality and tumor size was observed for FFLP (p=0.001). In IPTW-adjusted subgroup analysis of patients with tumor size >2 cm, the SBRT group had a higher FFLP compared with the RFA group (HR, 0.153; p<0.001).
Conclusion
SBRT and RFA showed similar local control in the treatment of patients with CRLM. Tumor size was an independent prognostic factor for local control and SBRT may be preferred for larger tumors.

Citations

Citations to this article as recorded by  
  • Ablative techniques in colorectal liver metastases: A systematic review, descriptive summary of practice, and recommendations for optimal data reporting
    Wee Han Ng, Catarina Machado, Alice Rooney, Robert Jones, Jonathan Rees, Samir Pathak
    European Journal of Surgical Oncology.2025; 51(2): 109487.     CrossRef
  • Treatment of Oligometastatic GI Cancers
    Clayton T. Marcinak, Patrick B. Schwartz, Mustafa M. Basree, Newton Hurst, Michael Bassetti, Jeremy D. Kratz, Nataliya V. Uboha
    American Society of Clinical Oncology Educational Book.2024;[Epub]     CrossRef
  • Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations
    D. Pezzulla, G. Chiloiro, E. M. Lima, G. Macchia, C. Romano, S. Reina, G. Panza, S. Cilla, A. G. Morganti, F. Cellini, M. A. Gambacorta, F. Deodato
    Clinical & Experimental Metastasis.2024; 41(5): 667.     CrossRef
  • Interventionelle Therapieoptionen bei oligometastasierten Tumoren
    Max Seidensticker
    Forum.2024; 39(5): 340.     CrossRef
  • Efficacy and safety of B-ultrasound-guided radiofrequency ablation in the treatment of primary liver cancer: Systematic review and meta-analysis
    Xiong Zhang, Hong-Yi Zhu, Ming Yuan
    World Journal of Gastrointestinal Surgery.2024; 16(9): 2986.     CrossRef
  • Analysis of alkaline phosphatase and γ-glutamyltransferase after radiofrequency ablation of primary liver cancer: A retrospective study
    Wen-Yu Huang, Sheng Zheng, Dan Zhu, Ying-Lang Zeng, Juan Yang, Xue-Li Zeng, Pei Liu, Shun-Ling Zhang, Ming Yuan, Zhi-Xia Wang
    World Journal of Gastrointestinal Surgery.2024; 16(9): 2860.     CrossRef
  • Recent trends in radiotherapy use for major cancers in Korea
    Kyungmi Yang, Jeong Eun Lee, Won Park, Yong Chan Ahn, Seung Jae Huh
    Japanese Journal of Clinical Oncology.2023; 53(12): 1177.     CrossRef
  • Combination of endoscopic ultrasound-guided radiofrequency ablation and adaptive radiation therapy for the treatment of lymph node metastases from colon adenocarcinoma: A case report
    Federica Borrelli de Andreis, Maria Alessandra Calegari, Angela Romano, Maria Gabriella Brizi, Luigi Sofo, Ivo Boskoski, Guido Costamagna, Fabia Attili
    Current Problems in Cancer: Case Reports.2023; 9: 100216.     CrossRef
  • Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis
    Chai Hong Rim, Jung Sue Lee, Soo Yeon Kim, Jinsil Seong
    JHEP Reports.2023; 5(1): 100594.     CrossRef
  • Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy
    Gyu Sang Yoo, Chai Hong Rim, Won Kyung Cho, Jae-Uk Jeong, Eui Kyu Chie, Hyeon-Min Cho, Jun Won Um, Yong Chan Ahn, Jong Hoon Lee
    Cancer Research and Treatment.2023; 55(3): 707.     CrossRef
  • Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century
    Sara Mheid, Stefan Allen, Sylvia S. W. Ng, William A. Hall, Nina N. Sanford, Todd A. Aguilera, Ahmed M. Elamir, Rana Bahij, Martijn P. W. Intven, Ganesh Radhakrishna, Issa Mohamad, Jeremy De Leon, Hendrick Tan, Shirley Lewis, Cihan Gani, Teo Stanecu, Vero
    Current Oncology.2023; 30(10): 9230.     CrossRef
  • Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade
    Koji Tomita, Yusuke Matsui, Mayu Uka, Noriyuki Umakoshi, Takahiro Kawabata, Kazuaki Munetomo, Shoma Nagata, Toshihiro Iguchi, Takao Hiraki
    Japanese Journal of Radiology.2022; 40(10): 1035.     CrossRef
  • 8,685 View
  • 286 Download
  • 10 Web of Science
  • 12 Crossref
Close layer
Radiofrequency Ablation for Metastatic Hepatic Tumor in Colorectal Carcinoma
Jung-Hye Choi, Myung-Ju Ahn, Hyunchul Rhim, Heung Woo Lee, Ho-Suk Oh, Young-Yeul Lee, Il-Young Choi, In-Soon Kim
Cancer Res Treat. 2004;36(2):128-131.   Published online April 30, 2004
DOI: https://doi.org/10.4143/crt.2004.36.2.128
AbstractAbstract PDFPubReaderePub
Purpose

The purpose of this study was to assess the efficacy and safety of radiofrequency ablation (RFA) to treat hepatic metastasis in patients with colorectal carcinoma.

Materials and Methods

Between May 1999 and July 2002, a total of 45 tumors in 24 patients with colorectal cancer were treated with RFA. Thirteen patients received systemic chemotherapy after the RFA procedure. The ablation was performed percutaneously under ultrasound guidance using cool-tip or expandable electrodes and an RF generator. The medical records as well as the CT scan results taken every 3 months were retrospectively reviewed.

Results

The median follow-up duration of the surviving patients was 11.7 months (4.6~32.2 months). Complete tumor necrosis was achieved in 17 patients (70.8%) on an immediate (<24 hrs) CT scan. The median survival was 17.1 months. The 1- and 2-year survival rates were 80.5 and 25.8%, respectively. In a univariate analysis, complete necrosis, tumor size and post-RFA chemotherapy were significant factors for survival. Nineteen of the 24 patients developed a recurrence or progressed (79.2%). The median progression free survival was 5.5 months. There were no treatment related deaths or serious adverse effects, with the exception of one case of respiratory failure.

Conclusion

These results suggest that RFA is a well-tolerated and effective method to treat hepatic metastasis in colorectal carcinomas.

Citations

Citations to this article as recorded by  
  • Single-centre survival analysis over 10 years after MR-guided radiofrequency ablation of liver metastases from different tumour entities
    Susann-Cathrin Olthof, Daniel Wessling, Moritz T. Winkelmann, Hansjörg Rempp, Konstantin Nikolaou, Rüdiger Hoffmann, Stephan Clasen
    Insights into Imaging.2022;[Epub]     CrossRef
  • Prognostic factors after ultrasound‐guided percutaneous ablation of colorectal liver metastases: A systematic review
    Jeanett Klubien, Andreas P. Kohl, Christian P. Nolsøe, Jacob Rosenberg, Hans‐Christian Pommergaard
    Australasian Journal of Ultrasound in Medicine.2018; 21(2): 87.     CrossRef
  • Impact of timing and cycles of systemic chemotherapy on survival outcome of colorectal liver metastases patients treated by percutaneous microwave ablation
    Kai Zhang, Jie Yu, Fubo Zhou, Xiaoling Yu, Xin Li, Jianbin Wang, Zhiyu Han, Zhigang Cheng, Ping Liang
    International Journal of Hyperthermia.2016; 32(5): 531.     CrossRef
  • Efficacy and safety of thermal ablation in patients with liver metastases
    Yingjun Liu, Shengping Li, Xiangbin Wan, Yi Li, Binkui Li, Yaqi Zhang, Yunfei Yuan, Yun Zheng
    European Journal of Gastroenterology & Hepatology.2013; 25(4): 442.     CrossRef
  • CT- versus coregistered FDG-PET/CT-based radiation therapy plans for conformal radiotherapy in colorectal liver metastases: a dosimetric comparison
    Cem Parlak, Erkan Topkan, Serhat Sonmez, Cem Onal, Mehmet Reyhan
    Japanese Journal of Radiology.2012; 30(8): 628.     CrossRef
  • 8,076 View
  • 56 Download
  • 5 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP